Team

Dr. Sebastian Pünzeler

Partner

Sebastian has more than 10 years of experience in the life science industry, from applied and basic research to venture capital investments and portfolio management. He joined the Apollo investment team as a Partner in August 2022 and focuses on venture investing and company building. Prior to that, Sebastian was a Principal with coparion, a venture capital firm investing in early-stage technology startups. In this role, he established and managed the coparion life science division and led all life science related investment activities from deal sourcing to execution. He supported nine life science portfolio companies as board member including pharmaceutical (HepaRegeniX, Thermosome, Tacalyx, Tubulis, Cardior Pharmaceuticals and Abalos Therapeutics) and medical technology (Fasciotens and Protembis) companies in various development stages, working on different indications and exploiting diverse therapeutic entities. Before joining coparion in 2016, Sebastian started his VC career at Gimv, a European investment company, listed on Euronext Brussels. As an Analyst, he was involved in the evaluation and execution of Gimv’s investments in Topas Therapeutics and Breath Therapeutics. Sebastian holds a PhD in molecular biology from the International Max Planck Research School for Molecular Life Sciences (IMPRS-LS) Munich and the LMU Munich Medical Faculty. His research on novel histone variants and chromatin interactors resulted in several publications in renowned journals. Sebastian is a trained molecular biologist with a diploma from the RWTH Aachen University / the LMU Munich. He conducted his diploma research on fluorescent-labeled nanobodies in collaboration with the research tools startup ChromoTek.

LinkedInTwitter
Dr. Sebastian Pünzeler